Our reporters bring you news and highlights from BIO’s in-person and virtual events.
BIO 2026 Start-Up Stadium winner generates human data to improve clinical translation. Artificial intelligence is opening new possibilities for drug discovery. But in neuroscience, […]
BrainStorm Therapeutics combines brain organoids and AI for CNS drug discovery Read More »
The BIO 2026 Start-up Stadium winner targets a rare disease. As Herb Sarnoff sits in the hospital, waiting for a pain specialist to see
iNFixion seeks NF1 treatment by enhancing what the body is doing right Read More »
For years, advocates have pushed for more research and investment in women’s health. Now, it may be paying off. “I’m excited about the medicine
BIO 2026: Are we entering the ‘golden era’ of women’s health? Read More »
Generative genomics uses AI to analyze genetic sequences for innovative treatments. Every industry is racing to optimize AI in their operations. For many biotech
BIO 2026: Generative genomics helps biotechs design better, not just faster Read More »
The tap is opening up for venture capital in the biotech industry. Venture investment in biotech jumped 23% year-over-year in 2025 to $23 billion,
BIO 2026: How biotechs break the $100M barrier in funding rounds Read More »
Listening to people’s concerns about vaccines is key to helping them regain trust, according to experts promoting the need for life-saving immunizations. “We’ve all
BIO 2026: To restore trust in vaccines, listen to everyone’s concerns Read More »
“CAR-T cell therapies are remarkable drugs and are the gold standard for patients,” said Rachel Haurwitz, PhD, President & CEO of Caribou Biosciences. These
BIO 2026: Realizing the promise of CAR-T cell therapies Read More »
While the U.S. Food and Drug Administration (FDA) has faced significant change in recent years, industry leaders and agency officials alike say there are
BIO 2026: FDA leaders discuss restoring workforce, institutional knowledge Read More »
Industry leaders at BIO 2026 discussed the proposed PDUFA VIII next steps. After a year of discussion with the industry and 127 meetings with
BIO 2026: Industry PDUFA negotiators describe their agreement with FDA Read More »
Experts at the BIO International Convention examine the growth of the 340B drug pricing program, duplicate discounts, patient access, and calls for greater transparency.
BIO 2026: 340B faces growing calls for transparency, patient-focused reform Read More »
